It has been observed that CYP450 4A-derived 20-hydroxyeicosatetraenoic acid, in conjunction with the induction of pro-angiogenic growth factors by tumor-associated macrophages (TAMs), promotes angiogenesis during anti-VEGF treatment. The gene discussed is VEGFA; the disease is neoplasm.